Indonesia

Tuberculosis profile

Population 2014
Estimates of TB burden * 2014
Mortality (excludes HIV+TB)
Mortality (HIV+TB only)
Prevalence (includes HIV+TB)
Incidence (includes HIV+TB)
Incidence (HIV+TB only)

254 million
Number (thousands)
100 (66150)
22 (1332)
1 600 (1 3002 000)
1 000 (7001 400)
63 (4190)

Case detection, all forms (%)

Estimates of MDR-TB burden * 2014
% of TB cases with MDR-TB
MDR-TB cases among notified pulmonary
TB cases

Rate
(per 100 000 population)
41 (2659)
8.5 (5.213)
647 (513797)
399 (274546)
25 (1636)

80
40
0
1990

New
1.9 (1.42.5)
5 600 (4 2007 400)

2002

2006

2010

1000

1 100 (7701 600)

500

Total new and relapse

Previously treated, excluding relapses
Total cases notified

322 806
1 733
324 539

New
1 058 (<1%)

TB/HIV 2014
TB patients with known HIV status
HIV-positive TB patients
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
HIV-positive TB patients on antiretroviral therapy (ART)
HIV-positive people screened for TB
HIV-positive people provided with IPT
Treatment success rate and cohort size
New and relapse cases registered in 2013
Previously treated cases, excluding relapse, registered in 2013
HIV-positive TB cases, all types, registered in 2013
RR-/MDR-TB cases started on second-line treatment in 2012
XDR-TB cases started on second-line treatment in 2012

0
1990

Relapse
6 449
1 391
1

Number
15 074
2 355
963
624

(%)
(88)
(64)
(49)
(54)
(64)

1998

2002

2006

2010

Prevalence

600
400
200
0
1990

Retreatment
8 445 (88%)

1994

(Rate per 100 000 population per year)

Among 322 806 new and relapse cases:

23 170 (7%) cases aged under 15 years; male:female ratio: 1.4

Laboratories 2014
Smear (per 100 000 population)
Culture (per 5 million population)
Drug susceptibility testing (per 5 million population)
Sites performing Xpert MTB/RIF
Is second-line drug susceptibility testing available?

1998

(Rate per 100 000 population)

1500

Retreatment
12 (8.117)

New **
193 321
101 991
19 653

Reported cases of RR-/MDR-TB 2014

Cases tested for RR-/MDR-TB
Laboratory-confirmed RR-/MDR-TB cases
Patients started on MDR-TB treatment ***

1994

Mortality (excludes HIV+TB)

32 (2346)

TB case notifications 2014

Pulmonary, bacteriologically confirmed
Pulmonary, clinically diagnosed
Extrapulmonary

Financing TB control 2015

National TB programme budget (US$ millions)
% Funded domestically
% Funded internationally
% Unfunded

***
(Rate per 100 000 population per year)

Total **
9 503
1 812
1 284
(%)
(5)
(16)
(41)
(26)

Cohort
325 582
1 521
2 438
432
11

2.2
0.4
0.3
41
Yes, in country

133
13%
21%
66%

* Ranges represent uncertainty intervals

** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB

1994

1998

2002

2006

Notified (new and relapse)

Incidence (HIV+TB only)

2010

Incidence

(Number of patients)
3000
2000
1000
0
2003

2005

2007

2009

2011

2013

HIV-positive TB patients
on CPT
on ART
Treatment success rate (%)
90
70
50
30
1995 1997 1999 2001 2003 2005 2007 2009 2011
New
Retreatment
New and relapse
Retreatment, excluding
relapse
HIV-positive
RR-/MDR-TB
XDR-TB
Total budget (US$ millions)
150
100
50
0
2011

__
__

2012

Funded domestically
Unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2016-01-02

2013

__

2014

2015

Funded internationally

Data: www.who.int/tb/data